Physician profile
Itemad Badr
NPI 1659318657
$4,691.89
in general payments reported to CMS, 2019-2025
17 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $292 · 2021: $12.61 · 2022: $395 · 2023: $929 · 2024: $1,079 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.12 |
| Education | $327.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,611.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,100.82 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $853.89 | 2019-2025 | Dupixent |
| Genzyme Corporation | $342.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $202.46 | 2019-2025 | |
| Csl Behring | $117.27 | 2024-2025 | Andembry, Haegarda |
| Sanofi-Aventis U.S. LLC | $94.95 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.32 | 2019-2022 | |
| Optinose US, INC. | $53.23 | 2019-2022 | |
| Pfizer INC. | $50.05 | 2022-2023 | |
| Viatris Specialty LLC | $44.29 | 2025 | Yupelri |
| Amgen INC. | $37.76 | 2024 | Tezspire |
| Alk-Abello, INC | $34.33 | 2019 | |
| Genentech USA, INC. | $30.63 | 2021-2024 | Xolair |
| Octapharma USA, INC. | $28.45 | 2023 | Cutaquig |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $21.77 | 2025 | Alvesco |
| Kaleo, INC. | $13.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Itemad Badr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.